Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499471 | 0.85 | CYP2D6 (0.61) | CHRM2CHRM4CHRM1CHRM3CYP2D6 | |
| SCHEMBL23872457 | 0.85 | CYP2D6 (0.61) | CHRM2CHRM4CHRM1CHRM3CYP2D6 | |
| SCHEMBL4921518 | 0.85 | CYP2D6 (0.61) | CHRM2CHRM4CHRM1CHRM3CYP2D6 | |
| SCHEMBL10443302 | 0.81 | CHRM2 (0.52) | CHRM2CHRM4CHRM1CHRM3CYP2D6 | |
| SCHEMBL10981334 | 0.80 | CYP2D6 (0.54) | CYP2D6KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL10582145 | 0.80 | CYP2D6 (0.54) | CYP2D6KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL2644963 | 0.80 | CYP2D6 (0.54) | CYP2D6KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL7878308 | 0.79 | CHRM2 (0.58) | CHRM2CHRM4CHRM1CHRM3CYP2D6 | |
| SCHEMBL4964029 | 0.79 | KMT2A (0.70) | CHRM2CHRM4CHRM1CHRM3CYP2D6 | |
| SCHEMBL28200030 | 0.79 | CYP2D6 (0.52) | CYP2D6KMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620425-B1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-12-24 | — | — | EP | disclosed |
| CN-100398533-C | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | CN | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| CN-1774433-A | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1620425-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092156-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
| US-6013836-A | PARTICULARLY ACTIVE AGAINST MOTHS AND BEETLES AND THEIR INSECT GROWTH REGULATING ACTIVITY WITHOUT ADVERSE IMPACT ON BENEFICIAL INSECTS; CROPS; FORESTRY | ROHM AND HAAS COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5424333-A | Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines | ROHM AND HAAS COMPANY (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0361645-B1 | ORGANIC HYDRAZINE DERIVATIVES FOR PHARMACEUTICAL USE | ROHM AND HAAS COMPANY (US) | 1993-09-29 | — | — | EP | disclosed |
| US-5117057-A | Insecticidal N' substituted-N-N'-disubstituted-hydrazines | ROHM AND HAAS COMPANY (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0361645-A2 | Organic hydrazine derivatives for pharmaceutical use | ROHM AND HAAS COMPANY (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | GLP1R, GCGR, GPR119 | CHRM2 404/4885CHRM4 530/4885CHRM1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.